MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity
Nanna M. Jensen,YuHong Fu,Cristine Betzer,Hongyun Li,Sara Elfarrash,Ali H. Shaib,Donatus Krah,Zagorka Vitic,Lasse Reimer,Hjalte Gram,Vladimir Buchman,Mark Denham,Silvio O. Rizzoli,Glenda M. Halliday,Poul Henning Jensen
DOI: https://doi.org/10.1101/2024.07.08.602186
2024-07-08
Abstract:Lewy pathology, consisting of Lewy bodies and Lewy neurites, is the pathological hallmark of synucleinopathies such as Parkinson's disease and dementia with Lewy bodies, but it is generally thought to represent late-stage pathological changes. In contrast, alpha-synuclein oligomers are regarded as early-stage pathology, likely involved in disease progression and cellular toxicity. Oligomers, however, are not detected by standard immunohistochemistry but require specific detection techniques such as the proximity ligation assay (PLA). Here, we describe the MJF-14 PLA, a new PLA towards aggregated alpha-synuclein with unprecedented specificity, attained by the utilization of aggregate conformation-specific alpha-synuclein antibody MJFR-14-6-4-2 (hereafter MJF-14). Signal in the assay directly correlates with alpha-synuclein aggregation in SH-SY5Y cells, as treatment with aggregation inhibitor ASI1D significantly lowers PLA signal. In human cortical neurons, MJF-14 PLA detects pre-formed fibril-induced aggregation, especially prominent when using stealth PFFs invisible to the MJF-14 antibody. Co-labelling of MJF-14 PLA and pS129-alpha-synuclein immunofluorescence in post-mortem dementia with Lewy bodies cases showed that while the MJF-14 PLA reveals extensive non-inclusion pathology, it is not sensitive towards Lewy bodies. In Parkinson's disease brain, direct comparison of PLA and IHC with the MJF-14 antibody, combined with machine learning-based quantification, showed striking alpha-synuclein pathology preceding the formation of conventional Lewy pathology. The majority of the PLA-revealed non-inclusion pathology was found in the neuropil, including some clearly located in the presynaptic terminals. With this work, we introduce an improved alpha-synuclein aggregate PLA to uncover abundant non-inclusion pathology, which deserves future validation with multiple brain bank resources and in different synucleinopathies.
Neuroscience